In a report released yesterday, Hartaj Singh from Oppenheimer assigned a Buy rating to Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $5. The company’s shares closed yesterday at $0.37, close to its 52-week low of $0.33.
Singh said:
“Actinium (ATNM) filed 1Q18 financials on 5/10. We sat down with management in mid-April (request note), and believe that with an increasingly clear line of sight to Iomab-B pivotal Phase 3 data (1H19, potential BLA filing 1H20) and mid-stage data in the growing Actimab CD33 program, ATNM is on track to significantly re-rate in 2H18. We update our estimates based on OPEX trends and remain bullish (request previous reports).”
According to TipRanks.com, Singh is a 5-star analyst with an average return of 18.2% and a 48.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Actinium Pharmaceuticals is Strong Buy and the average price target is $3.58, representing an 872.8% upside.
In a report issued on May 23, B.Riley FBR also maintained a Buy rating on the stock with a $2.75 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.50 and a one-year low of $0.33. Currently, Actinium Pharmaceuticals has an average volume of 890.9K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATNM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers. It targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company was founded in 1993 and is headquartered in New York, NY.
